In a previous study, MB49luc bladder tumor weights were reduced from 339 ± 61 mg to 137 ± 36 mg in non–T cell depleted NHS-muIL12–treated mice, while no such reductions were evident in NHS-muIL12–treated mice depleted of either CD4+ (bladder weights: 298 ± 76 mg) or CD8+ T cells (bladder weights: 456 ± 101 mg) [27], (b) regression of the MB49luc bladder tumors occurs at low doses of NHS-muIL12 (i.e., 0.4 μg/injection), and (c) previous results demonstrate that targeting the PD1/PD-L1 axis also mediates regression of the MB49luc bladder tumors [22]. This evidence concerns the gene CD274 and urinary bladder neoplasm.